Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. - Wikidata - awgldk - TriplyDB

Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

http://www.wikidata.org/entity/Q33587106

about

Tumor refractoriness to anti-VEGF therapy Receptor tyrosine kinase-mediated angiogenesis The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Effect of the vascular endothelial growth factor expression level on angiopoietin-2-mediated nasopharyngeal carcinoma growth.Measuring Vascular Permeability In Vivo Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway Angiopoietin-4 increases permeability of blood vessels and promotes lymphatic dilation.Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric Fab Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Current status and future directions of anti-angiogenic therapy for gliomas Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemia Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden.Vascular normalization: a real benefit?Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?Signaling pathways governing tumor angiogenesis.Insights into cell-to-cell and cell-to-blood-vessel communications in the brain: in vivo multiphoton microscopy.Targeting angiopoietin-2 signaling in cancer therapy.Understanding and targeting resistance to anti-angiogenic therapies.Pericytes: a double-edged sword in cancer therapy.Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.A novel mouse model of anterior segment dysgenesis (ASD): conditional deletion of Tsc1 disrupts ciliary body and iris development Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells.Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy Distinct Expression of Various Angiogenesis Factors in Mice Brain After Whole-Brain Irradiation by X-ray.Leishmania major Infection-Induced VEGF-A/VEGFR-2 Signaling Promotes Lymphangiogenesis That Controls Disease.Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells.Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.

P2860

Q26747678-B7C102BE-D8F1-43ED-B556-5EBCFAC15D04 Q27001612-3C8558BE-BB78-4747-A233-77169171A844 Q27025579-0E9692FA-83C2-4691-99CE-9561C92673D3 Q30469815-3AAB64D5-4A58-415E-8662-B5AE4A198803 Q30471456-3E0486FC-A841-43CE-AE1C-2500D2E2AE88 Q33588642-9316FAB1-2514-493F-9233-0577A8B8ACCC Q33699854-4DE3E234-F6AC-4C0B-AE95-B1DB576F161C Q34230220-FC9164B7-84F3-4BD9-AFB0-5482C3552341 Q34293163-585FE36F-E6B4-43EE-B19D-0385FD7DEEF1 Q34470585-1D5E2B98-8F9D-4CD7-A0FD-AE7D7ACA9B74 Q34548319-9555A690-40D3-4FEC-8789-75B44E8FC378 Q35042985-9F73DC72-4806-4F6D-A0BF-D4DB9D39B738 Q35310168-6141D15F-DF25-4D2E-A654-469786E596D1 Q35632471-1BC72B66-372C-4D88-993E-C395D5AD100C Q35662815-CE0AF139-CAE5-4552-B1AB-CF167F168BF4 Q35895174-0337BA89-04B8-466C-93B0-75B51EFC7396 Q36428702-2FDF4244-008F-45BC-8657-AD8B0EA8AB5D Q36618235-04899555-E829-4CF7-B1DD-64B72667664C Q36655378-C1465EB6-A184-4BBB-9AF3-651EED105A09 Q36831553-25A96ADE-689B-4735-A9EE-DEC4B1CD6348 Q36831642-37ECB5DE-E74D-45EA-8EC1-34D7F5A2708C Q37106787-6DF594B7-087F-479A-9C49-62405198670B Q37340643-0BF3421E-556F-4EA1-8AD8-3BBE9574F3F9 Q37747100-7387587E-5A5E-46FA-A30C-98D6F1A9BF8A Q37884454-7316E4AE-1298-426F-9603-1EB3B6C4D2A7 Q37921797-DE9CE057-ECED-43B0-9369-A8304E3C6CC0 Q37972805-211D50AA-9EDE-40BC-9DEB-41745869F2A3 Q38084177-475DF221-F3C4-4020-A7DF-BE73DF6EDF33 Q38101997-42C7A5ED-C25F-49A0-B86A-7526E50B8E8C Q38133568-882B713D-BB29-49C4-B3B5-AD3E117ED027 Q38241791-ECBCCBB1-F2BF-4A08-B989-01DFA1BB9C79 Q38736319-91397143-C27B-49A8-A7AD-6704901610A8 Q38751824-CA77C507-281E-464F-BE80-2AAD3406D0E6 Q38763633-321C7F98-61BA-4C2F-95DF-D2DA7BF2ACA7 Q38821641-1AE295CE-B3EC-41CA-A704-FF929D8F222D Q38888160-B58AAD78-BC40-424D-A730-19FACF14BB04 Q39155128-28BA26E1-B035-4AC2-B87E-41BBBD7F4F76 Q39543850-13AC1B59-8D25-400B-8B54-E7F0E1DF8005 Q39552934-BBA47D57-91E0-4359-ADA0-6316A9BDECDD Q40997333-2CEEC576-76F7-434A-90A2-E513BD49C7EB

P2860

Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

http://www.wikidata.org/entity/Q33587106

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@ast

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@en

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@nl

type

label

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@ast

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@en

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@nl

prefLabel

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@ast

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@en

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@nl

P1433

Q33587106-84375863-3658-44FB-9DD9-D3FBCD2FB830

P1476

Q33587106-AE48D4C1-B4C8-4D13-A1CD-663D465F70A9

P2093

Q33587106-14149B2D-E384-47A5-96AE-4EA59122545B

Q33587106-358D728E-F36F-4062-A5B5-E0714BCD07C3

Q33587106-50862FFB-542C-4D1F-9634-0910EAA8C5E4

Q33587106-6C481BF0-19DD-45DD-A73B-04FEFBF15DFE

Q33587106-96A7EEC3-21FF-423A-8721-3FEBF02E805D

Q33587106-ADF2BED4-A39B-40CA-A92F-AE4992F25E41

Q33587106-AF5EEF21-3B5C-485D-8D78-B19D245516B4

Q33587106-FB695980-0E4B-4CE1-8E04-E7FC1E972BD6

Q33587106-FD209A55-7228-4897-A4AA-6561C75C1381

Q33587106-FEE6BCC2-5C9E-4CFE-9BF4-9EA62E218395

P2860

Q33587106-13F45135-6891-4535-B7BE-45DA89D11F8B

Q33587106-199BE4FF-E08D-44DB-8B50-C67DB9DE7315

Q33587106-426F5225-5976-447A-9CA0-BF840584EEE4

Q33587106-47C5502B-6B17-4500-9A21-572570DA093B

Q33587106-4C33214A-BCDE-4175-8955-6FDD2C90440B

Q33587106-54174D96-424B-451E-9F66-1BCBBA232381

Q33587106-58DF96EB-6EA9-4DF1-8303-866BC8FF384A

Q33587106-5E54716C-762B-467C-9FB9-761826C41ABC

Q33587106-6B98E011-F624-41F8-8CD6-73C1EDDC286C

Q33587106-6D6F79D4-9175-4A4F-9C18-1182CBF746C4

P304

Q33587106-B48CD253-EAC3-41EB-BE2C-6745B764C798

P31

Q33587106-5CD99A6A-A1AA-4C74-AF5B-4A168823410B

P356

Q33587106-0A569AEB-63FA-4D3C-847E-5852C9BB6B74

P407

Q33587106-142287E4-0A0B-47F6-ACAA-2CB5C9BB12DD

P433

Q33587106-58674EC8-9340-47A5-8D92-6D1B9C6511D0

P478

Q33587106-5D0C2C23-4D15-42B5-B288-9157FC3B0CBB

P577

Q33587106-FD852509-BB09-45F7-94DD-3BC807D0F4AF

P5875

Q33587106-D67A69ED-6689-43A1-99E9-0B176E5D953F

P698

Q33587106-3BD592DC-BEB3-4538-BF0A-25B8B6D00E20

P932

Q33587106-BF69B2E4-E7B4-47F4-B320-7A39EF3B1F88

P356

1078-0432.CCR-09-3073

P1433

Clinical Cancer Research

P1476

Angiopoietin-2 interferes with ...... nefit in mice bearing gliomas.

@en

P2093

A Gregory Sorensen

http://www.w3.org/2001/XMLSchema#string

Annemarie M A de Graaf

http://www.w3.org/2001/XMLSchema#string

Christian T Farrar

http://www.w3.org/2001/XMLSchema#string

Dai Fukumura

http://www.w3.org/2001/XMLSchema#string

Elisabeth Niemeyer

http://www.w3.org/2001/XMLSchema#string

Lance L Munn

http://www.w3.org/2001/XMLSchema#string

Nathaniel D Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

Rakesh K Jain

http://www.w3.org/2001/XMLSchema#string

Sung-Suk Chae

http://www.w3.org/2001/XMLSchema#string

Walid S Kamoun

http://www.w3.org/2001/XMLSchema#string

P2860

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks.

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Biomarkers of response and resistance to antiangiogenic therapy.

Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102

P304

3618-3627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-3073

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44629516

http://www.w3.org/2001/XMLSchema#string

P698

20501615

http://www.w3.org/2001/XMLSchema#string

P932

2905497

http://www.w3.org/2001/XMLSchema#string